<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;1267_tetrachlorodibenzo_p_dioxin&quot;}]"></div>

# 1267_tetrachlorodibenzo_p_dioxin

- **generic name:** not captured
- **ATC codes:** not captured
- **DrugBank:** not captured · **PubChem:** [CID 38524](https://pubchem.ncbi.nlm.nih.gov/compound/38524)
- **groups:** not captured

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-08 10:37 | 4:26 | 0/0/0 | 0/0/0 | 0/0/0 | 32,423/1,409 | ollama / qwen3.8:27b-mtp-q8_0 | 41 | 7/34 | 40/1 | 0 |

## popPK records

_not available_

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 237 matched, 53 returned
- **screened:** 12  ·  **relevant:** 12
- **records:** 0  ·  extracted 0  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** True

## Full text wanted

_1 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Sorg_2009.pdf` | Sorg O et al., 2,3,7,8-tetrachlorodibenzo-p-dioxin (TC…, Lancet (London, England) (2009) | popPK | 8 | [10.1016/S0140-6736(09)60912-0](https://doi.org/10.1016/S0140-6736(09)60912-0) | [19660807](https://pubmed.ncbi.nlm.nih.gov/19660807) | The paper reports a specific half-life (15.4 months) for TCDD in a human case study, but lacks other quantitative compartmental parameters like clearance or volume of distribution. |

<sub>queue written 2026-09-08T10:37:39.343909+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Abraham_2002 | irrelevant | 0 | 0 | The study focuses on CYP1A2 enzyme induction using caffeine as a probe drug, not on the pharmacokinetic parameters of TCDD itself. |
| popPK | Afzal_2026 | irrelevant | 0 | 0 | The paper studies antimicrobial activity of plant terpenoids against bacteria and does not involve the drug 1267_tetrachlorodibenzo_p_dioxin or any pharmacokinetic parameters. |
| PD | Afzal_2026 | irrelevant | 0 | 0 | The paper studies the antimicrobial activity of terpenoids from *Anagallis foemina* against *Acinetobacter baumannii* and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Andersen_1997 | relevant | 8 | 2 | The paper describes a PBPK model for TCDD and analyzes literature PK data, but the specific quantitative disposition parameters (CL, V, etc.) are not explicitly listed in the provided text, only binding constants and model descriptions. |
| popPK | Angrish_2013 | irrelevant | 0 | 0 | The study investigates the effects of TCDD on lipid metabolism and gene expression, not its pharmacokinetic disposition parameters (CL, V, t1/2). |
| popPK | Besné_2026 | irrelevant | 0 | 0 | The paper is a neurophysiology study on anti-seizure medications and does not report pharmacokinetic parameters for 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Besné_2026 | irrelevant | 0 | 0 | The paper studies the mechanism of anti-seizure medications (ASMs) in epilepsy patients and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin or any toxicological dose-response relationship for that substance. |
| popPK | Bhuju_2021 | irrelevant | 0 | 0 | The study focuses on cutaneous effects and toxicology of TCDD exposure, not pharmacokinetic parameter estimation (CL, V, etc.). |
| popPK | Brewster_1988 | irrelevant | 0 | 0 | The study investigates 2,3,4,7,8-pentachlorodibenzofuran (4PeCDF), not 1267_tetrachlorodibenzo_p_dioxin (TCDD), which is only mentioned as a comparator for toxicity. |
| popPK | Brouwer_1995 | irrelevant | 0 | 0 | The paper is a review of developmental toxicity and does not report quantitative pharmacokinetic parameters for 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Buckley_1995 | irrelevant | 2 | 0 | The text is a review/summary of PBPK models for TCDD without providing specific quantitative parameter values (CL, V, etc.) in the evidence. |
| popPK | Byard_1987 | irrelevant | 2 | 1 | The paper is a review of toxicological significance and body burdens rather than a primary pharmacokinetic study reporting quantitative disposition parameters like clearance or volume of distribution. |
| popPK | Börnsen_2026 | irrelevant | 0 | 0 | The paper describes the molecular mechanism of bacterial efflux pump inhibitors (BDM91531) and does not involve the drug 1267_tetrachlorodibenzo_p_dioxin or report any pharmacokinetic parameters. |
| PD | Börnsen_2026 | irrelevant | 0 | 0 | The paper studies the molecular mechanism of BDM91531, a bacterial antibiotic efflux pump inhibitor, and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Cerlesi_1989 | irrelevant | 0 | 0 | The paper reports environmental persistence half-life in soil, not pharmacokinetic parameters (CL, V, ka) for a biological subject. |
| popPK | Chahoud_1989 | irrelevant | 2 | 0 | The study focuses on reproductive toxicity and mortality in rats, and while the title mentions pharmacokinetics, the provided evidence contains no quantitative PK parameters (CL, V, t1/2) for TCDD. |
| popPK | Chikhale_2026 | irrelevant | 0 | 0 | The paper is an in-silico study on Mycobacterium tuberculosis thymidylate kinase inhibitors and does not involve the drug 1267_tetrachlorodibenzo_p_dioxin or report any pharmacokinetic parameters. |
| PD | Chikhale_2026 | irrelevant | 0 | 0 | The paper studies natural compounds targeting Mycobacterium tuberculosis thymidylate kinase and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin or any toxicodynamic dose-response relationships for it. |
| popPK | Dao_2021 | irrelevant | 0 | 0 | The study focuses on in-vitro enzymatic biodegradation mechanisms and does not report pharmacokinetic parameters (CL, V, etc.) for the drug. |
| popPK | DeVito_1995 | irrelevant | 2 | 1 | The paper is a toxicological study focusing on EROD induction and relative potency rather than a PK study reporting quantitative disposition parameters (CL, V, Q) for the subject drug. |
| popPK | De_1994 | irrelevant | 1 | 0 | The study focuses on the toxicological effect of TCDD on thymic atrophy and only mentions a qualitative half-life estimate (&gt;16 days) without reporting quantitative pharmacokinetic parameters like clearance or volume. |
| popPK | De_2025 | irrelevant | 0 | 0 | The paper focuses on the development of dual GPBAR1 and LIFR modulators for liver fibrosis and does not involve the drug 1267_tetrachlorodibenzo_p_dioxin or report any pharmacokinetic parameters. |
| PD | De_2025 | irrelevant | 0 | 0 | The paper studies estradienone derivatives for liver fibrosis and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Dencker_1985 | irrelevant | 0 | 0 | The paper is a review of the Ah-receptor and toxicity mechanisms, not a pharmacokinetic study reporting quantitative disposition parameters. |
| popPK | Diamond_2026 | irrelevant | 0 | 0 | The paper describes the mechanism of action and structural biology of ribosome inhibitors (interdictors) for cancer treatment and does not contain any pharmacokinetic data for 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Diamond_2026 | irrelevant | 0 | 0 | The paper studies synthetic ribosome inhibitors (interdictors) and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Diaz_2025 | irrelevant | 0 | 0 | The paper is an immunological study investigating the effects of TCDD on AHR activation and immune responses to infection, not a pharmacokinetic study reporting quantitative disposition parameters like clearance or volume. |
| popPK | Diliberto_1996 | relevant | 8 | 2 | The study reports qualitative PK parameters (absorption %, tissue distribution %) for TCDD in rats but lacks quantitative compartmental parameters (CL, V, ka) required for population PK modeling. |
| popPK | Dong_2016 | irrelevant | 2 | 0 | The paper focuses on cancer dose-response uncertainty analysis and risk estimation (ED01) rather than reporting specific quantitative pharmacokinetic parameters (CL, V, Q, ka) for the drug. |
| popPK | Dong_2020 | irrelevant | 0 | 0 | The paper studies 12378-polychlorinated dibenzo-p-dioxin (P5CDD), which is a different congener than the target drug 1267-tetrachlorodibenzo-p-dioxin. |
| popPK | Dreute_2025 | irrelevant | 0 | 0 | The paper investigates the synergistic effects of metabolic inhibitors (GNE-140 and BMS-986205) on cancer cells and does not mention or study 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Dreute_2025 | irrelevant | 0 | 0 | The paper studies the metabolic inhibitors (R)-GNE-140 and BMS-986205 (Linrodostat) for cancer therapy and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | EFSA_2026 | irrelevant | 0 | 0 | The paper is an EFSA safety assessment of microorganisms (QPS list) and contains no pharmacokinetic data for 1267_tetrachlorodibenzo_p_dioxin. |
| PD | EFSA_2026 | irrelevant | 0 | 0 | The paper concerns the safety assessment of microbiological agents (bacteria and fungi) for food and feed, and does not study 1,2,6,7-Tetrachlorodibenzo-p-dioxin or report any toxicodynamic data for it. |
| popPK | Eltahir_2025 | irrelevant | 0 | 0 | The paper studies chalcones from Aizoon africanum and does not involve the drug 1267_tetrachlorodibenzo_p_dioxin or report any pharmacokinetic parameters for it. |
| PD | Eltahir_2025 | irrelevant | 0 | 0 | The paper studies chalcones isolated from Aizoon africanum, not 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Eskenazi_2018 | irrelevant | 0 | 0 | The paper is a review of health outcomes following the Seveso accident and does not report quantitative pharmacokinetic parameters for TCDD. |
| popPK | Faiad_2016 | irrelevant | 0 | 0 | The paper describes the development of an immuno-detection assay (ELISA) for dioxins using a recombinant protein, not a pharmacokinetic study, and contains no PK parameters. |
| popPK | Ferrero_2025 | irrelevant | 0 | 0 | The paper is a molecular dynamics simulation study of melatonin encapsulated in cyclodextrin nanosponges and does not involve the drug 1267_tetrachlorodibenzo_p_dioxin or report any pharmacokinetic parameters. |
| PD | Ferrero_2025 | irrelevant | 0 | 0 | The paper studies the molecular dynamics of melatonin encapsulated in β-cyclodextrin nanosponges and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin or any toxicodynamic relationships. |
| popPK | Frakes_1993 | irrelevant | 2 | 0 | The study reports bioaccumulation factors (BAFs) for TCDD in fish, which are ecological exposure metrics rather than pharmacokinetic parameters (CL, V, ka) for a specific subject drug. |
| popPK | Fries_1990 | irrelevant | 2 | 0 | The paper is an environmental risk assessment that discusses pharmacokinetic models and half-lives qualitatively but does not report original quantitative PK parameter values (CL, V, etc.) for the drug. |
| popPK | Funseth_2002 | irrelevant | 0 | 0 | The study investigates the toxicological and pathological effects of TCDD on viral infection and trace elements in mice, not its pharmacokinetic disposition parameters. |
| popPK | Fürst_1994 | irrelevant | 0 | 0 | The paper reports environmental concentrations of TCDD in human milk but does not provide pharmacokinetic parameters (clearance, volume, half-life) or a PK model. |
| popPK | Geusau_2001 | irrelevant | 2 | 1 | The study reports specific elimination rates and concentrations in two patients but does not provide a compartmental or population pharmacokinetic model with standard parameters like clearance (CL) or volume (V). |
| popPK | Geyer_2002 | irrelevant | 2 | 2 | The paper is a critical review that reports half-lives but lacks the specific quantitative disposition parameters (clearance, volume, compartmental model) required for population pharmacokinetic extraction. |
| popPK | Glass_2024 | irrelevant | 0 | 0 | The paper is a computational study on bacterial metabolic networks and antimicrobial targets, containing no pharmacokinetic data for 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Glass_2024 | irrelevant | 0 | 0 | The paper studies antimicrobial targets in bacterial pathogens using metabolic modeling and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Golor_2001 | irrelevant | 0 | 0 | The study investigates 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (H7CDD), not 1267_tetrachlorodibenzo_p_dioxin (TCDD), which is only used as a comparator. |
| popPK | González-Barbosa_2017 | irrelevant | 0 | 0 | The study is a mechanistic investigation of gene expression and protein degradation, not a pharmacokinetic study, and reports no quantitative disposition parameters for the drug. |
| popPK | Haymer_2026 | irrelevant | 0 | 0 | The paper studies cannabinoid receptor 2 agonists (amprenavir analogues) and does not report pharmacokinetic parameters for 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Haymer_2026 | irrelevant | 0 | 0 | The paper studies the repurposing of the HIV protease inhibitor amprenavir as a cannabinoid receptor 2 agonist and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Hernandez-Leyva_2026 | irrelevant | 0 | 0 | The paper focuses on gut microbiota and breath volatile organic compounds (VOCs) and does not report pharmacokinetic parameters for 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Hernandez-Leyva_2026 | irrelevant | 0 | 0 | The paper studies the relationship between gut microbiota and breath volatile organic compounds (VOCs) and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin or any toxicodynamic dose-response relationships. |
| popPK | Huff_1991 | irrelevant | 2 | 0 | The paper is a review of carcinogenesis that mentions general pharmacokinetic properties (absorption percentage, half-life ranges) but does not report specific quantitative disposition parameters (CL, V, Q, ka) or a compartmental model for the subject drug. |
| popPK | Imani_2025 | irrelevant | 0 | 0 | The paper focuses on the preparation of a wound dressing using lawsone and MOFs, and does not study the pharmacokinetics of 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Imani_2025 | irrelevant | 0 | 0 | The paper studies lawsone (2-hydroxy-1,4-naphthoquinone) extracted from Lawsonia inermis for wound dressing applications, not 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Inganäs_2025 | irrelevant | 0 | 0 | The paper is a computational and in-vitro study on PROTAC membrane interactions and does not report pharmacokinetic parameters for 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Inganäs_2025 | irrelevant | 0 | 0 | The paper studies the membrane interactions of PROTACs (proteolysis targeting chimeras) and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin or report any toxicodynamic data for it. |
| popPK | Jain_2021 | irrelevant | 0 | 0 | The paper reports serum concentration trends associated with kidney function stages, not pharmacokinetic disposition parameters (CL, V, ka) for the specific drug 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Jana_2026 | irrelevant | 0 | 0 | The paper studies the antifungal metabolite SM06, not 1267_tetrachlorodibenzo_p_dioxin, and contains no pharmacokinetic parameters for the target drug. |
| PD | Jana_2026 | irrelevant | 0 | 0 | The paper studies an antifungal metabolite named SM06 (an indole dimer) produced by a bacterium, not 1,2,6,7-Tetrachlorodibenzo-p-dioxin (TCDD). |
| popPK | Joffin_2018 | relevant | 8 | 2 | The study uses a PBPK model to simulate TCDD kinetics, but specific numeric parameter values (CL, V, etc.) are not present in the provided text. |
| popPK | Johnson_1992 | irrelevant | 2 | 1 | The study reports serum concentrations and assumes a half-life for exposure modeling, but does not provide quantitative compartmental PK parameters (CL, V, Q) or a population PK model for the drug. |
| popPK | Kerger_2012 | irrelevant | 2 | 1 | The paper is an epidemiological study on diabetes risk and reverse causation, not a pharmacokinetic study reporting quantitative disposition parameters (CL, V, Q, ka) for the drug. |
| popPK | Kerkvliet_1993 | irrelevant | 0 | 0 | The study focuses on the immunotoxic effects of TCDD on peritoneal exudate cells and does not report pharmacokinetic parameters such as clearance, volume, or half-life. |
| popPK | Kimura_2014 | irrelevant | 0 | 0 | The paper is an immunological study on aryl hydrocarbon receptor and Listeria infection, containing no pharmacokinetic data for 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Koch_1995 | relevant | 8 | 2 | The study reports toxicokinetic evaluations for TCDD in rats, but the specific quantitative parameter values (clearance, volume, etc.) are not present in the provided abstract text. |
| popPK | Koppe_1995 | irrelevant | 0 | 0 | The paper is a review/epidemiological study on dioxin exposure in breast milk and does not report quantitative pharmacokinetic parameters (CL, V, etc.) for the specific compound 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Krowke_1989 | irrelevant | 2 | 0 | The study reports qualitative trends in tissue concentrations over time but does not provide quantitative pharmacokinetic parameters such as clearance, volume of distribution, or half-life. |
| popPK | LaKind_2000 | irrelevant | 2 | 0 | The paper focuses on exposure modeling and dose distributions from breast milk rather than reporting quantitative pharmacokinetic parameters (CL, V, Q, ka) for the drug. |
| popPK | Lambiase_2022 | irrelevant | 0 | 0 | The paper reports bioaccumulation and biotransfer factors for environmental contaminants (PCDD/Fs) in hens, not pharmacokinetic parameters (CL, V, ka) for the specific drug 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Larsen_2006 | irrelevant | 0 | 0 | The paper is a risk assessment review focusing on toxicology and intake limits, not a pharmacokinetic study reporting quantitative disposition parameters for the specific drug 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Legraverend_1984 | irrelevant | 0 | 0 | The study focuses on benzo[a]pyrene pharmacokinetics and toxicity, with 2,3,7,8-tetrachlorodibenzo-p-dioxin mentioned only as a non-detectable imprinting agent without any PK parameters reported. |
| popPK | Leung_1988 | irrelevant | 1 | 0 | The paper is a review proposing an occupational exposure limit based on toxicology and risk assessment, not a pharmacokinetic study reporting quantitative disposition parameters like clearance or volume. |
| popPK | Leung_1990 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of the analog [125I]-2-iodo-3,7,8-trichlorodibenzo-p-dioxin (ITCDD), not the target drug 1267_tetrachlorodibenzo_p_dioxin (TCDD), which was only used as a pretreatment inducer. |
| popPK | Ma_2019 | irrelevant | 0 | 0 | The paper is a mechanistic toxicology study on aryl hydrocarbon receptor activity and does not report pharmacokinetic parameters for TCDD. |
| popPK | Maese_2025 | irrelevant | 0 | 0 | The paper reports pharmacokinetic parameters for JZP458 (recombinant Erwinia asparaginase), not 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Maese_2025 | irrelevant | 0 | 0 | The paper studies Recombinant Erwinia asparaginase (JZP458), not 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Marques_2024 | irrelevant | 0 | 0 | The paper reports population pharmacokinetic parameters for salbutamol, not 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Marques_2024 | irrelevant | 0 | 0 | The paper studies the pharmacokinetics of salbutamol, not 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Matsumoto_2015 | irrelevant | 0 | 0 | The study focuses on 2,3,4,7,8-pentachlorodibenzofuran (PeCDF), not the target drug 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Mc_2026 | irrelevant | 0 | 0 | The paper studies the pharmacokinetics of CAR-T cell therapies (axicabtagene ciloleucel and brexucabtagene autoleucel), not 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Mc_2026 | irrelevant | 0 | 0 | The paper studies the pharmacokinetics of CAR-T cell therapies (axicabtagene ciloleucel and brexucabtagene autoleucel) and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Meyer_2014 | irrelevant | 0 | 0 | The paper studies alkylated picene and chrysene derivatives, not 1267_tetrachlorodibenzo_p_dioxin, and reports no pharmacokinetic parameters. |
| popPK | Michalek_1995 | irrelevant | 0 | 0 | The paper is an epidemiological study investigating exposure indices and body burden, not a pharmacokinetic study reporting quantitative disposition parameters like clearance or volume. |
| popPK | Micheletti_2007 | irrelevant | 0 | 0 | The paper is an ecological risk assessment study focusing on bioaccumulation and hazard quotients, not a pharmacokinetic study reporting quantitative disposition parameters (CL, V, etc.) for the specific drug. |
| popPK | Miniero_2001 | irrelevant | 2 | 0 | The paper is a review/regression analysis of half-life data from the literature rather than an original PK study reporting specific quantitative disposition parameters (CL, V, Q) for the subject drug. |
| popPK | Moenning_2023 | irrelevant | 0 | 0 | The study focuses on polychlorinated biphenyls (PCBs), not 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Morales_2025 | irrelevant | 0 | 0 | The paper studies the hypoglycemic effect of a plant extract (Acalypha argomuelleri) and does not involve the drug 1267_tetrachlorodibenzo_p_dioxin or report any pharmacokinetic parameters. |
| PD | Morales_2025 | irrelevant | 0 | 0 | The paper studies the hypoglycemic effect of an aqueous extract from *Acalypha argomuelleri*, not 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Moran_1986 | irrelevant | 0 | 0 | The study investigates the effects of TCDD on immunoglobulin A (IgA) levels and organ weights, not the pharmacokinetic disposition parameters (CL, V, t1/2) of TCDD itself. |
| popPK | Mukerjee_1998 | irrelevant | 2 | 1 | The paper is a review of environmental exposure and toxicity that mentions a human elimination half-life range (7-11 years) but lacks a compartmental model, clearance, or volume of distribution parameters required for population PK extraction. |
| popPK | Myers_2026 | irrelevant | 0 | 0 | The paper studies the pharmacokinetics of BMX-001 (MnTnBuOE-2-PyP), not 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Myers_2026 | irrelevant | 0 | 0 | The paper studies BMX-001 (a superoxide dismutase mimetic) and its effects on cancer and normal tissue, and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Nakata_1997 | irrelevant | 0 | 0 | The paper focuses on PCB bioaccumulation in seals and does not report pharmacokinetic parameters for 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Neal_1985 | irrelevant | 2 | 0 | The paper is a mechanistic review of toxicity and receptor binding that discusses half-lives qualitatively but does not report quantitative PK parameters (CL, V, Q) or provide the numeric values from the referenced tables. |
| popPK | Olson_1994 | irrelevant | 1 | 0 | The study is an in-vitro mechanistic investigation of hepatic uptake and metabolism using isolated hepatocytes and microsomes, not a pharmacokinetic study reporting quantitative disposition parameters (CL, V, etc.) for the drug in vivo. |
| popPK | Ouyang_2021 | irrelevant | 0 | 0 | The paper studies the bioremediation of PCB 118 (pentachlorodiphenyl), not 1267_tetrachlorodibenzo_p_dioxin, and reports environmental degradation half-lives rather than pharmacokinetic parameters. |
| popPK | Patrick_2020 | irrelevant | 0 | 0 | The paper is a review of diabetes and toxicant exposure that does not report quantitative pharmacokinetic parameters for 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Paustenbach_1992 | irrelevant | 0 | 0 | The paper is a risk assessment regarding environmental exposure and cleanup levels, not a pharmacokinetic study reporting quantitative disposition parameters (CL, V, etc.) for the drug. |
| popPK | Pegram_1995 | irrelevant | 2 | 0 | The study reports tissue distribution ratios and concentrations rather than quantitative pharmacokinetic parameters like clearance, volume of distribution, or half-life. |
| popPK | Pelcl_2018 | irrelevant | 0 | 0 | The paper is a clinical epidemiological study examining metabolic outcomes (diabetes, cardiovascular disease) in TCDD-exposed patients, not a pharmacokinetic study reporting quantitative disposition parameters like clearance or volume. |
| popPK | Pollitt_1999 | irrelevant | 0 | 0 | The paper discusses 2,3,7,8-tetrachlorodibenzodioxin (TCDD), not 1267_tetrachlorodibenzo_p_dioxin, and provides no quantitative PK parameters for the target drug. |
| popPK | Prazdnova_2026 | irrelevant | 0 | 0 | The paper is a computational molecular docking study of Bacillus lipopeptides interacting with receptors (NOX4, EGFR, PDGFR, OCTN2) and does not involve the drug 1267_tetrachlorodibenzo_p_dioxin or report any pharmacokinetic parameters. |
| PD | Prazdnova_2026 | irrelevant | 0 | 0 | The paper studies Bacillus-derived lipopeptides (e.g., plipastatin, fengycin) and their interactions with receptors, and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Purificação_2025 | irrelevant | 0 | 0 | The paper is a structural biology study on the crystal structure of Dihydroorotate Dehydrogenase in complex with lapachol, and does not contain any pharmacokinetic data for 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Purificação_2025 | irrelevant | 0 | 0 | The paper studies the crystallographic structure of human dihydroorotate dehydrogenase in complex with lapachol, not 1,2,6,7-tetrachlorodibenzo-p-dioxin. |
| popPK | Qiu_2021 | irrelevant | 0 | 0 | The study reports in-vitro biodegradation kinetics (half-life 5.21d) by a fungus, not pharmacokinetic disposition parameters (CL, V, Q) in a biological organism. |
| popPK | Rannug_2018 | irrelevant | 0 | 0 | The paper is a review focusing on the physiological role of FICZ and AHR signaling, with no quantitative pharmacokinetic parameters reported for TCDD. |
| popPK | Rauf_2025 | irrelevant | 0 | 0 | The paper investigates the inhibitory potential of plant metabolites against beta-glucuronidase via molecular docking and does not involve the drug 1267_tetrachlorodibenzo_p_dioxin or report any pharmacokinetic parameters. |
| PD | Rauf_2025 | irrelevant | 0 | 0 | The paper studies secondary metabolites from *Fernandoa adenophylla* (such as Lapachol and Indanone derivatives) as inhibitors of beta-glucuronidase, and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Rosenthal_1989 | irrelevant | 0 | 0 | The study focuses on the toxicological effects of TCDD on endotoxin clearance and mortality, not on the pharmacokinetic disposition parameters (CL, V, t1/2) of TCDD itself. |
| popPK | S_2025 | irrelevant | 0 | 0 | The paper studies novel triazole derivatives as antimicrobial agents and does not involve the drug 1267_tetrachlorodibenzo_p_dioxin or report any pharmacokinetic parameters for it. |
| PD | S_2025 | irrelevant | 0 | 0 | The paper studies the synthesis and antimicrobial properties of novel triazole-hydrazide compounds, not 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Saleh_2023 | irrelevant | 0 | 0 | The paper studies the pharmacokinetics of 10 other drugs (e.g., cyclophosphamide, quinidine) in mice and does not mention or report data for 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Saleh_2023 | irrelevant | 0 | 0 | The paper studies the pharmacokinetics of 10 unrelated drugs (e.g., cyclophosphamide, quinidine) in mice and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin or report any toxicodynamic data. |
| popPK | Schrenk_1998 | irrelevant | 0 | 0 | The paper is a review of the biochemical effects of TCDD on drug-metabolizing enzymes and does not report quantitative pharmacokinetic parameters (CL, V, etc.) for TCDD itself. |
| popPK | Scialli_2015 | irrelevant | 0 | 0 | The paper is a review discussing TCDD concentrations in human milk and exposure sources, but it does not report quantitative pharmacokinetic parameters (CL, V, ka, etc.) for the drug. |
| popPK | Silva_2024 | irrelevant | 0 | 0 | The paper reports pharmacokinetic parameters for APX3330, not 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Silva_2024 | irrelevant | 0 | 0 | The paper studies the pharmacokinetics of APX3330, a selective APE1/Ref-1 inhibitor, and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin (TCDD). |
| popPK | Sugita-Konishi_2003 | irrelevant | 0 | 0 | The study focuses on immunological effects (susceptibility to Listeria infection) rather than pharmacokinetic disposition parameters for TCDD. |
| popPK | Sun_2022 | irrelevant | 0 | 0 | The paper studies the microbial degradation of halogenated polycyclic aromatic hydrocarbons (HPAHs) in water, not the pharmacokinetics of 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Takimoto_1992 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of gene expression (ALDH-3 induction) in hepatoma cells, not a pharmacokinetic study reporting disposition parameters for TCDD. |
| popPK | Tue_2024 | irrelevant | 2 | 1 | The study focuses on brominated dibenzofurans, with TCDD serving only as a comparator, and lacks specific compartmental PK parameters (CL, V) for TCDD. |
| popPK | Tuomisto_2006 | irrelevant | 0 | 0 | The paper is an epidemiological study on cancer risk and body burden, not a pharmacokinetic study, and it does not report quantitative PK parameters (CL, V, etc.) for 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Van_1989 | irrelevant | 0 | 0 | The study investigates polychlorinated dibenzofurans (PCDFs), not the target drug 1267_tetrachlorodibenzo_p_dioxin (TCDD), which is only mentioned as a comparator. |
| popPK | Vatankhah_2026 | irrelevant | 0 | 0 | The paper is a narrative review on the developmental toxicity of TCDD (craniofacial/dental defects) and does not report quantitative pharmacokinetic parameters (CL, V, Q, ka) or compartmental models. |
| popPK | Vats_2025 | irrelevant | 0 | 0 | The paper is a review of the medicinal plant Tecomella undulata and does not contain any pharmacokinetic data for 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Vats_2025 | irrelevant | 0 | 0 | The paper is a review of the plant Tecomella undulata and does not study 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Wang_2022 | irrelevant | 0 | 0 | The study focuses on polychlorinated naphthalenes (PCNs), not 1267_tetrachlorodibenzo_p_dioxin, which is only mentioned as a comparator for half-life. |
| popPK | Ward_1978 | irrelevant | 0 | 0 | The study is an environmental fate analysis in an aquatic model, not a pharmacokinetic study reporting disposition parameters (CL, V, etc.) for a biological subject. |
| popPK | Weatherford-Pratt_2025 | irrelevant | 0 | 0 | The paper is a chemistry study on the synthesis and spectroscopic analysis of deuterated cyclohexenes, not a pharmacokinetic study of 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Weatherford-Pratt_2025 | irrelevant | 0 | 0 | The paper studies the synthesis of deuterated cyclohexenes and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin or any toxicological endpoints. |
| popPK | Weber_1982 | irrelevant | 2 | 0 | The study focuses on the disposition of TCDD *metabolites* in rats rather than the parent drug 1267_tetrachlorodibenzo_p_dioxin, and it reports qualitative recovery percentages rather than quantitative PK parameters (CL, V, ka) for the subject drug. |
| popPK | Wu_2014 | irrelevant | 2 | 0 | The study reports qualitative trends and correlations for elimination rate constants (k) but does not provide specific quantitative PK parameters (CL, V, t1/2) for the specific congener 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | Xu_2025 | irrelevant | 0 | 0 | The paper describes chemical synthesis and protein modification methods, containing no pharmacokinetic data for 1267_tetrachlorodibenzo_p_dioxin. |
| PD | Xu_2025 | irrelevant | 0 | 0 | The paper studies N-alkylpyridinium reagents for protein functionalization and does not investigate 1,2,6,7-Tetrachlorodibenzo-p-dioxin. |
| popPK | Yang_2018 | irrelevant | 0 | 0 | The paper is an exposure assessment study reporting chemical concentrations (TEQs) in blood, not a pharmacokinetic study reporting quantitative disposition parameters (CL, V, ka) for 1267_tetrachlorodibenzo_p_dioxin. |
| popPK | van_2000 | irrelevant | 2 | 0 | The text is a qualitative review of toxicokinetic principles and PBPK modeling concepts without reporting specific quantitative PK parameter values (CL, V, etc.) for 1267_tetrachlorodibenzo_p_dioxin. |

---
<sub>Generated by `docs.py` (scholarv2)</sub>
